Weight Loss Sale

Life Extension Magazine

LE Magazine November 2003
A Comprehensive Guide to Preventative Blood Testing
By Penny Baron

How To Order Blood Tests

You can order blood tests by mail or by calling (800) 208-3444.

As soon as you place your order, you will be sent a package with information regarding the location of the nearest blood-drawing stations, a Request for Phlebotomy form, and a Test Requisition form. All tests must be prepaid.

At your convenience, you can then take the Request for Phlebotomy form and Requisition to the designated blood-drawing station in your area. A phlebotomist will draw the appropriate specimens of your blood. You (or your physician) will be mailed your test results. These results will show if you have any abnormalities. If the results show abnormalities, you should make sure you show these results to your personal physician, who can determine if you have any serious problems and what you can do about them.

You can also request a free consultation with one of the Foundation’s doctors to help interpret your test results to make certain that you stay in optimal ranges.

If longevity risk factors such as glucose, homocysteine, C-reactive protein, fibrinogen, or other tests are abnormal, slightly elevated or below normal, for example—you can take nutritional steps to reverse the trend. You can repeat the test in 45-60 days, and then chart your progress in improving your health and your chances of living longer in good health.

Health Software Programs

Keeping track of personal health information can be challenging. It’s not a simple task to maintain test reports; vaccine records; medications; doctors’ visits; allergies; illnesses; fitness, food, blood pressure and weight diaries; and other health-associated information.

But doing so will empower you to take charge of your health and that of your family. Having this information at your fingertips not only allows you to communicate more effectively with your health care provider, but also enables you to spot trends (changes) in your health status—possibly well before your physician. Too often individuals aren’t diagnosed with health problems until they are far advanced.

Keeping health “diaries” and mapping trends can also enable you to move more easily towards certain goals (i.e., weight loss, lowering risk of cardiovascular disease by following test markers, general fitness, etc). Studies have shown that just by virtue of having to maintaining written records, patients are often more compliant with therapies.

In order to record and track your health data with ease, we have identified three inexpensive (or free) software programs that promise to help you manage all of your personal health information as well as track data trends for you and your family:

CapMed PHR $44.95—PC only (not Mac-compatible)
CapMed Corporation - 302-429-9109
Note: Cannot download from the internet.

Health-Minder $35—PC only (not Mac-compatible)
Note: Can download free for 60-day trial.

Health tracker Shareware/free—Mac OS only (not PC-compatible)
Note: download only from the Apple computer website.


1. ADVANCEDATA, from Vital & Health Statistics of The National Center for Health Statistics, US Department of Health and Education Welfare, No. 5, February 22, 1977, Public Health Service - Health Resources Administration. “A Comparison of Levels of Serum Cholesterol of Adults 18-74 Years of Age in the Untied States in 1960-62 and 1971-74.”

2. Mahanonda N, Leowattana W, Kangkagate C, Lolekha P, Pokum S.Homocysteine and restenosis after percutaneous coronary intervention. J Med Assoc Thai 2001 Dec;84 Suppl 3:S636-44.

3. Robinson K, Mayer EL, Miller DP, et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and inde pendent reversible risk factors for coronary artery disease. Circulation 1995 Nov 15;92(10):2825-30.

4. Tenover JS. Effects of testosterone supple mentation in the aging male. J Clin Endocrinol Metab 1992 Oct;75(4):1092-8.

5. Phillips GB, Pinkernell BH, Jing TY The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 1994 May;14(5):701-6.

6. Gelfand MM, Wiita B. Androgen and estrogen-androgen hormone replacement therapy: a review of the safety literature, 1941 to 1996. Clin Ther 1997 May-Jun;19(3):383-404; discussion 367-8.

7. Gooren LJ Endocrine aspects of ageing in the male. Mol Cell Endocrinol 1998 Oct 25;145(1-2):153-9.8. Barrett-Connor E, Von Muhlen DG, Kritz- Silverstein D Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab 1999 Feb;84(2):573-7.

9. Schweiger U, Deuschle M, Weber B, Korner A, Lammers CH, Schmider J, Gotthardt U, Heuser I Testosterone, gonadotropin, and cortisol secretion in male patients with major depression. Psychosom Med 1999 May-Jun;61(3):292-6.

10. Rabkin JG; Wagner GJ; Rabkin R Testosterone therapy for human immunod eficiency virus-positive men with and with out hypogonadism. J Clin Psychopharmacol Feb 1999, 19 (1) p19-27.

11. Seidman SN, Walsh BT Testosterone and depression in aging men. Am J Geriatr Psychiatry 1999 Winter;7(1):18-33.

12. The Testosterone Syndrome, Eugene Shippen and Fryer, W., p. 116.

13. Maximize Your Vitality & Potency, Jonathan Wright and Lenard, L., pp. 146-47.

14. Super T, Karlis Ullis, M.D., Shackman, J., and Ptacek, G., pp. 43-44.

15. Tan RS, Pu SJ. The andropause and memo ry loss: is there a link between androgen decline and dementia in the aging male? Asian J Androl 2001 Sep;3(3):169-74.

16. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995 Jul;43(1):55-68.

17. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk fac tor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam

Study. Ann Intern Med 2000 Feb 15;132(4):270-8.

18. Michalopoulou G, Alevizaki M, Piperingos G, et al. High serum cholesterol levels in persons with “high-normal” TSH levels: should one extend the definition of subclin ical hypothyroidism? Eur J Endocrinol 1998; 138: 141-45.

19. Pollock MA, Sturrock A, Marshall K, et al. Thyroxine treatment in patients with symp toms of hypothyroidism but thyroid func tion tests within the reference range: ran domized double blind placebo controlled crossover trial. BMJ 2001 Oct 20;323(7318):891-5.

20. Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM. Folate, Vitamin B12, Homocysteine, and the MTHFR 677CT Polymorphism in Anxiety and Depression. The Hordaland Homocysteine Study. Archives of General Psychiatry 2003;60:618-626.

21. Koenig W, Sund M, Fröhlich M, Fischer H- G, Löwel H, Döring A, Hutchinson WL, Pepys MB. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-242 http://circ.ahajournals.org/cgi/reprint/ 99/2/237.pdf

22. Pradhan AD, et al. C-reactive protein, interleukin 6, and risk of developing Type II diabetes mellitus. JAMA 2001; 286:327-34.

23. Teunissen, C.E. et al. Inflammation mark ers in relation to cognition in a healthy aging population. J Neuroimmunol 2003;134:142-50.

24. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovas cular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.http://circ.ahajournals.org/ cgi/reprint/107/3/499.pdf

25. Catalona WJ, Partin AW, Slawin KM, et al. Use of percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic dis ease. A prospective multicenter clinical trial. JAMA 1998; 279:1542-1547.

26. Punglia RS, D’Amico AV, Catalona WJ, Roehl KA, Karen M. Kuntz KM. Effect of Verification Bias on Screening for Prostate Cancer by Measurement of Prostate- Specific Antigen. NEJM 2003;349:335-342.

27. Reuters Health: Precursor of PSA accurate ly detects prostate cancer 7/15/03.

28. Reuters Health: Exercise tougher at begin ning of menstrual cycle. 7/5/2002).

29. Dinarello CA. Proinflammatory cytokines. Chest 2000;118:503-508. http://www.chestjournal.org/ cgi/reprint/118/2/503.pdf.

30. Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, Malarkey WB, Glaser R. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. PNAS 2003;100:9090-9095. http://www.pnas.org/cgi/reprint/100/15/9090.pdf

31. Verdecchia P. MD, et al. Risk of cardiovas cular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects. JACC, 2002;39:878-885.

32. Mendall MA, Patel P, Asante M, Ballam L, Morris J, Strachan DP, Camm AJ, Northfield TC. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart. 1997;78(3):273-7.

33. Lappe JM, Muhlestein JB, Carlquist JF, Davis BF, Horne BD, Anderson JL. Inlerleukin-1 beta predicts death or myocardial infarction independently of high-sensitivity C-reactive protein and stan dard risk factors in patients with coronary artery disease. Abstracts – Myocardial Ischemia and Infarction 841-2. JACC 2002.

34. Brambilla F, Bellodi L, Perna G, Bertani A, Panerai A, Sacerdote P. Plasma Iinterleukin-1beta concentrations in panic disorder. Psychiatry Research 1994;54:135- 142.

35. Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y, Yamaguchi A, Yoshiki S, Matsuda T, Hirano T, et al. IL-6 is pro duced by osteoblasts and induces bone resorption. J Immunol 1990;15:3297-303. http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db= PubMed&list_uids=2121824&dopt= Abstract.

36. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate 2000;15: 239-242. http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db=PubMed& list_uids=10639195&dopt =Abstract.

37. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wachholder S, Ettinger WH, Heimovitz H, Cohen HJ, Wallace R. Associations of ele vated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999;106:506-12.

38. Cappola AR, Xue Q-L, Ferrucci L, Guralnik JM, Volpato S, Fried LP. Insulin- like growth factor I and interleukin-6 con tribute synergistically to disabiltity and mor tality in older women. J Clin Endocrinology and Metabolism 2003;88:2019-2025.

39. Ferruci L, Harris TB, Guralnik JM, Tracy RP, Corti M-C, Cohen HJ, Penninx B, Pahor M, Wallace R, Havlik RJ. Serum IL- 6 level and the development of disability in older persons. J Am Geriatr Soc 1999;47:639-646.

40. Radack K, Deck C, Huster G. Dietary sup plementation with low-dose fish oils lowers fibrinogen levels. Ann Intern Med 189;111:757-758.

41. Folsom AR, Wu KK, Shahar E, Davis CE. Association of hemostatic variables with prevalent cardiovascular disease and asymp tomatic carotid artery atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Arterioscler Thromb 1993;13:1829-1836.

42. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000;343:457-462. http://content.nejm.org/ cgi/reprint/343/7/457.pdf

43. Walston J, McBurnie MA, Newman A, Tracy RP, Kop WJ, Hirsch C, Gottdiener J, Fried LP, for the Cardiovascular Health Study Investigators. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities. Arch Intern Med 2002;162:2333-2341. http://archinte.ama- assn.org/cgi/reprint/162/20/2333.pdf

44. Burguera JL, Burguera M, Gallignani M, Alarcon OM, Burgueera JA. Blood serum selenium in the province of Merida, Venezuela, related to sex, cancer incidence and soil selenium content. J Trace Elem Electrolytes Health Dis 1990;4:73-77.

45. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exqui site dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991:87:1402-1412.

46. Carrillo-Jimenez) Carillo-Jimenez R, Treadwell TL, Goldfine H, Buenano A, Lamas GA, Hennekens CH. Brain natri uretic peptide and HIV-related cardiomy opathy. AIDS Read 2002;12:501-508. http://www.medscape.com/ viewarti cle/444895_print

47. Kawai K, Hata K, Takaoka H, Kawai H, Yokoyama M. Plasma brain natriuretic pep tide as a novel therapeutic indicator in idio pathic dilated cardiomyopathy during beta- blocker therapy: a potential of hormone- guided treatment. Am Heart J 2001;141: 925-932. http://www.medscape.com/viewarti cle/409235_print

48. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neuro hormonal predictors of left ventricular func tion and prognosis after myocardial infarc tion. Circulation 1998;97:1921-1929.

49. Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, Clopton P, Alberto J, Hlavin P, Maisel AS. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. JACC 2001;37:379-385.

50. Adapted from LEF:http://www.lef.org/what shot /2001_02.html#hpfi)

51. Cheng-Lai A, Levine A. Rosiglitazone. An agent from the thiazolidinedione class for the treatment of type 2 diabetes. Heart Disease 2000;2:326-333.

52. Krentz AJ, Bailey CJ, Melander A. Thiazolidinediones for type 2 diabetes. BMJ 2000;321:235-236.

53. Ogawa S, Takeuchi K, Ito S. Plasma BNP levels in the treatment of type 2 diabetes with piglitazone. J Clin Endocrinol Metab 2003;88:3993-3996. http://jcem.endojour nals.org/cgi/reprint/88/8/3993.pdf

54. Burguera JL, Burguera M, Gallignani M, Alarcon OM, Burgueera JA. Blood serum selenium in the province of Merida, Venezuela, related to sex, cancer incidence and soil selenium content. J Trace Elem Electrolytes Health Dis 1990;4:73-77.

55. Fleet JC. Dietary selenium repletion may reduce cancer incidence in people at high risk who live in areas with low soil selenium. Nutr Rev 1997;55:277-9.

56. Knekt P, Marniemi J, Teppo L, Heliovaara M, Aromaa A. Is low selenium status a risk factor for lung cancer? Am J Epidemiol 1998;148:975-82.

57. Patterson BH and Levander OA. Naturally occurring selenium compounds in cancer chemoprevention trials: A workshop sum mary. Cancer Epidemiol Prev 1997;6:63-9.

58. Russo MW, Murray SC, Wurzelmann JI, Woosley JT, Sandler RS. Plasma selenium levels and the risk of colorectal adenomas. Nutr Cancer 1997;28:125-9. Biomarkers Prev 1997;6:63-9.

59. Shamberger RJ. The genotoxicity of seleni um. Mutat Res 1985;154:29-48.

60. Young KL and Lee PN. Intervention studies on cancer. Eur J Cancer Prev 1999;8:91-103.

61. Fleet JC. Dietary selenium repletion may reduce cancer incidence in people at high risk who live in areas with low soil selenium. Nutr Rev 1997;55:277-9.

62. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M. Prevalence of insulin resistance in metabol ic disorders: the Bruneck Study. Diabetes 1998;47:1643-1649. http://diabetes.dia betesjournals.org/cgi/reprint/47/10/1643.pdf

63. Arad Y, Newstein D, Cadet F, Roth M, Guerci AD. Association of multiple risk factors and insulin resistancew ith increased prevalence of asymptomatic coronary artery disease by an electon-beam computed tomographic study. Arterioscler Thromb Vasc Biol 2001;21:2051-2058.

64. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in Type II diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002;25:1135-1141.

65. University of Pittsburgh http://www.discov er.pitt.edu/media/pcc020916/sciInsulinResistant.html

66. Barton-Davis ER, Shoturma DI, Musaro A, Rosenthal N, Sweeney HL. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci 1998;95:15,603-15,607.

67. Ruiz-Torres A, Soares de Meo Kirzner M. Ageing and longevity are related to growth hormone/insulin-like growth factor-1 secre tion. Gerontology 2002;48;401-407.

68. Van den Beld AW, Bots ML, Janssen JAMLL Pols HAP, Lamberts SWJ, Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol 2004;157:25-31.

69. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-B levels. Nature Medicine 2002;8:1390-1397.

70. Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Research 2003;63:3991-3994.

71. Wilczak N, de Vos RAI, De Keyser J. Free insulin-like growth factor (IGF)-1 and IGF binding proteins 2,5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis. Lancet 2003;361:1007-1011.

72. Di Marzio L, Moretti S, D’Alo S, Zazzeroni F, Marcellini S, Smacchia C, et al. Acetyl-L- carnitine administration increases insulin- like growth factor 1 levels in asymptomatic HIV-1-infected subjects: correlation with its suppressive effect on lymphocyte apoptosis and ceramide generation. Clin Immunol. 1999 Jul;92(1):103-10.

73. Ladenson PW et al. American Thyroid Association guidelines for detection of thy roid dysfunction. Arch Intern Med. 2000;160:573-5.

74. Vanderpump MP, Tunbridge WM, French JM et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol 1995;43:55-68

75. Hak AE, Pols HA, Visser TJ, et al. Subclinical hypothyroidism is an independ ent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study. Ann Intern Med 2000;132:270-8.

76. Michalopoulou G, Alevizaki M, Piperingos G. et al. High serum cholesterol levels in persons with “high-normal” TSH levels: should one extend the definition of subclini cal hypothyroidism. Eur J Endocrinol 1998;138:141-145.

77. Garnero P, Hausherr E, Chapey M-C, et al. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study. J Bone Min Res 1996;11:1531-1538.

78. Hesley RP, Shepard KA, Jankins DK, et al. Monitoring estrogen replacement therapy and identifying rapid bone losers with an immunoassay for deoxypyridinoline. Osteoporosis Int 1998;8:159-164.

79. Scheidt-Nave Scheidt-Nave C, Bismar H, Leidig-Bruckner G, Woitge H, Seibel MJ, Ziegler R, Pfeilschifter J. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab 2001;86:2032-2042. http://jcem.endojour nals.org/cgi/reprint/86/5/2032.pdf

80. Lakatos P, Foldes J, Horvath C, Kiss L, Tatrai A, Takacs I, Tarjan G, Stern P. Serum interleukin-6 and bone metabolism in patients with thyroid function disorders. J Clin Endocrinol Metab 1997;82:78-81. http://jcem.endojournals.org/ cgi/reprint/82/1/78.pdf